Decrease in Osteoporotic Fracture in the Western Kitakyushu Region by the STOP-Fx Study

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2023 May 29

PMID 37247111

Authors

Yoshiaki Yamanaka

Satoshi Ikeda

Eiji Hatakeyama

Ken Sabanai

Hiroaki Tanaka

Satoshi Nishida

Yukichi Zenke

Takafumi Tajima

Manabu Tsukamoto

Hinako Obara

Kimiaki Kawano

Akinori Sakai

Affiliations

Soon will be listed here.

Abstract

Introduction: The Seamless Treatment of Osteoporosis against Fractures (STOP-Fx) study was initiated to provide and continue therapeutic interventions for registered patients with osteoporotic fractures.

Materials And Methods: Women who visited six hospitals in the western Kitakyushu area for osteoporotic fractures between October 2016 and December 2018 were included in the study. Data collection for primary and secondary outcomes was conducted from October 2018 to December 2020, 2 years after STOP-Fx study enrollment. The primary outcome included the number of surgeries for osteoporotic fractures after the STOP-Fx study intervention, while secondary outcomes were the intervention rate of osteoporosis treatment, incidence and timing of secondary fractures, and factors associated with secondary fractures and loss to follow-up.

Results: Concerning the primary outcome, the number of surgeries for osteoporotic fractures decreased since the STOP-Fx study initiation: 813 in 2017, 786 in 2018, 754 in 2019, 716 in 2020, and 683 in 2021. Regarding the secondary outcome, of the 805 patients enrolled, 445 were available for follow-up at 24 months. Of the 279 patients who were untreated for osteoporosis at enrollment, 255 (91%) were on treatment at 24 months. There were 28 secondary fractures, which were associated with increased tartrate-resistant acid phosphatase-5b and decreased lumbar spine bone mineral density during enrollment in the STOP-Fx study.

Conclusion: As the demographics and medical area served by six hospitals in the western Kitakyushu region have not changed significantly since the STOP-Fx study initiation, the STOP-Fx study may have contributed in decreasing the number of osteoporotic fractures.

References

Iba K, Dohke T, Takada J, Sasaki K, Sonoda T, Hanaka M . Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years. J Orthop Sci. 2017; 23(1):127-131. DOI: 10.1016/j.jos.2017.09.008. View

Kishimoto H, Maehara M . Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos. 2015; 10:231. PMC: 4545179. DOI: 10.1007/s11657-015-0231-6. View

Dell R, Greene D . Is osteoporosis disease management cost effective?. Curr Osteoporos Rep. 2010; 8(1):49-55. DOI: 10.1007/s11914-010-0009-0. View

PAYNE R, Little A, Williams R, Milner J . Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4(5893):643-6. PMC: 1587636. DOI: 10.1136/bmj.4.5893.643. View

Bawa H, Weick J, Dirschl D . Anti-Osteoporotic Therapy After Fragility Fracture Lowers Rate of Subsequent Fracture: Analysis of a Large Population Sample. J Bone Joint Surg Am. 2015; 97(19):1555-62. DOI: 10.2106/JBJS.N.01275. View

Myrtle J, Norman A . Vitamin D: A cholecalciferol metabolite highly active in promoting intestinal calcium transport. Science. 1971; 171(3966):79-82. DOI: 10.1126/science.171.3966.79. View

Tahtela R, Seppanen J, Laitinen K, Katajamaki A, Risteli J, Valimaki M . Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int. 2004; 16(9):1109-16. DOI: 10.1007/s00198-004-1819-7. View

Nenonen A, Cheng S, Ivaska K, Alatalo S, Lehtimaki T, Schmidt-Gayk H . Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res. 2005; 20(10):1804-12. DOI: 10.1359/JBMR.050403. View

Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung M . Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2010; 26(3):530-7. DOI: 10.1002/jbmr.251. View

10.

Hauschka P, Lian J, Cole D, Gundberg C . Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989; 69(3):990-1047. DOI: 10.1152/physrev.1989.69.3.990. View

11.

Hodges S, Akesson K, Vergnaud P, Obrant K, Delmas P . Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res. 1993; 8(10):1241-5. DOI: 10.1002/jbmr.5650081012. View

12.

Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K . Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab. 2013; 32(3):290-7. DOI: 10.1007/s00774-013-0490-5. View

13.

Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H . Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab. 2008; 26(3):260-4. DOI: 10.1007/s00774-007-0823-3. View

14.

Lindsay R, Silverman S, Cooper C, Hanley D, Barton I, Broy S . Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285(3):320-3. DOI: 10.1001/jama.285.3.320. View

15.

Iconaru L, Charles A, Baleanu F, Surquin M, Benoit F, Mugisha A . Prediction of an Imminent Fracture After an Index Fracture - Models Derived From the Frisbee Cohort. J Bone Miner Res. 2021; 37(1):59-67. DOI: 10.1002/jbmr.4432. View

16.

Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K . Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int. 2008; 20(8):1429-37. PMC: 2708326. DOI: 10.1007/s00198-008-0816-7. View

17.

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

18.

Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799-809. PMC: 2324066. DOI: 10.1056/NEJMoa074941. View

19.

Maricic M, Adachi J, Sarkar S, Wu W, Wong M, Harper K . Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med. 2002; 162(10):1140-3. DOI: 10.1001/archinte.162.10.1140. View

20.

Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I . Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014; 99(7):2599-607. PMC: 4191553. DOI: 10.1210/jc.2013-4175. View